Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 242Neoplasms, Plasma Cell 50Lymphoma 45Lymphoma, Mantle-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Non-Hodgkin 30Recurrence 29Lymphoma, Follicular 24Leukemia, Myeloid, Acute 24Lymphoma, Large B-Cell, Diffuse 23Waldenstrom Macroglobulinemia 22Lymphoma, B-Cell, Marginal Zone 20Leukemia 20Immunoglobulin Light-chain Amyloidosis 18Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 12Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Hodgkin Disease 11Burkitt Lymphoma 10Breast Neoplasms 10Lymphoma, T-Cell, Peripheral 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Lung Neoplasms 9Immunoblastic Lymphadenopathy 9Hematologic Neoplasms 9Prostatic Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell 8

Interventions

Rocuronium 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2ziprasidone 1venetoclax 1saponin QA-21V1 1perflutren 1finerenone 1empagliflozin 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Thalidomide 1Surveys and Questionnaires 1Stem Cell Transplantation 1Spironolactone 1Specimen Handling 1Simethicone 1Sevelamer 1Resistance Training 1Quillaja Saponins 1Protein Subunit Vaccines 1Polymorphism, Genetic 1Piperacillin, Tazobactam Drug Combination 1Phlebotomy 1Pentobarbital 1Oxycodone 1Nifedipine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Renal Insufficiency, Chronic × Bortezomib × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡